PropertyValue
?:definition
  • The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with crizotinib in patients with tumors that have ROS1 translocations, excluding non-small lung cell carcinomas.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5401195_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5401195_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all